AUS
NZ
UK
CA
USA
IND
Highlights
- BD authorized the repurchase of up to 10 million shares of its common stock.
- BD Medical expands U.S. manufacturing and introduces innovative needle-free blood collection.
- BD increases its fiscal 2025 Adjusted Diluted EPS guidance to $14.30–$14.60, reflecting 10% growth.
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced its financial results for the first quarter of fiscal 2025, ending December 31, 2024. The company delivered strong operational performance, contributing to its updated guidance for the full fiscal year. Alongside its quarterly results, BD highlighted key business developments and strategic investments that position it for continued growth.
One of the major announcements from BD’s board was the authorization of a new share repurchase program, allowing the company to repurchase up to 10 million shares of its common stock. This initiative adds to the shares available under the company’s previous authorization from 2021, underscoring BD’s commitment to delivering value to its shareholders.
In the BD Medical segment, the Medication Delivery Solutions business unit made significant investments in its U.S. manufacturing network to expand capacity for critical medical devices, including syringes, needles, and IV catheters. These investments are designed to meet the ongoing needs of the U.S. healthcare system, further strengthening BD’s position as a key player in the medical technology industry.
BD’s innovation in patient care was also highlighted with the introduction of the BD® PIVO™ Pro Needle-free Blood Collection Device, which is now being used by Carilion Clinic in Virginia. Carilion Clinic is the first health system in the state to offer needle-free in-patient blood draws, improving the patient experience by delivering a "One-Stick Patient Experience."
In the BD Life Sciences segment, the Specimen Management business unit announced an expansion of its fingertip blood testing, integrating BD’s MiniDraw™ Capillary Blood Collection System with Babson’s BetterWay technologies. This new solution is designed for use in urgent care centers, doctor’s offices, and other ambulatory care settings, broadening access to fast and reliable blood testing.
The Diagnostic Solutions business unit also made strides with the addition of the BD Onclarity™ HPV Assay to the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines. The assay’s ability to identify high-risk types of HPV sets it apart from other tests on the market. BD further announced that the assay would be part of a pioneering HPV self-collection study aimed at improving cervical cancer screening in underserved communities. This follows FDA approval earlier this year for HPV self-collection screening in healthcare settings.
In BD Biosciences, the company formed a collaboration with Biosero to integrate robotic systems with BD flow cytometers. This partnership aims to accelerate drug discovery and development, demonstrating BD’s continued focus on advancing technology to support biomedical research.
Looking ahead, BD has updated its fiscal 2025 guidance to reflect the strong operational performance seen in the first quarter. The company raised its Adjusted Diluted EPS guidance to a range of $14.30 to $14.60, representing a growth of 10% at the midpoint. This revised guidance incorporates an operational increase of $0.175 compared to the prior forecast and accounts for the impact of foreign currency fluctuations.
